Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
T2DM RR: 0.86), this effect did not achieve statistical significance within this analysis
Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study
Secondly, efficacy is the core criterion for evaluating drugs, and currently, multi-target GLP-1 drugs have shown better efficacy
10.2337/db16-0058 65 HayashiN.NakamoriS.HiraokaN.TsujieM.XundiX.TakanoT.et al (2004)
PG-102 demonstrated a clear dose-dependent reduction in both non-fasting blood glucose and HbA1c levels over a 3-month treatment period (Fig
US$ 21.49
US$ 21.22
US$ 25.34
US$ 27.41
